Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × mCRPC × enzalutamide × Clear all

Phase

Status

Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 29 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms, Castration-Resistant 2 Neoplasms 2 mCRPC 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Salivary Cancer 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Melanoma 1 Liposarcoma 1 Lethal Congenital Contracture Syndrome 2 1 Fibromatosis, Gingival, 2 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Dementia 1 Colorectal Neoplasms 1 Cognitive Dysfunction 1 Castration-resistant Prostate Cancer Patients with Oligometastases 1 Castrate Sensitive Prostate Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡